<DOC>
	<DOCNO>NCT02422199</DOCNO>
	<brief_summary>Pyrotinib oral tyrosine kinase inhibitor target HER-1 HER-2 receptor . This study randomize , multi-center , multinational , open-label , active-controlled , parallel design study combination pyrotinib plus capecitabine versus combination lapatinib plus capecitabine HER2+ MBC patient prior receive anthracyclin , taxane trastuzumab . Patients stratify weather prior use trastuzumab randomize 1:1 ratio one follow treatment arm : - Arm A : pyrotinib ( 400 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) - Arm B : lapatinib ( 1250 mg daily ) + capecitabine ( 1000 mg/m^2 twice daily ) Patients receive either arm therapy occurrence death , disease progression , unacceptable toxicity , specify withdrawal criterion .</brief_summary>
	<brief_title>A Study Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin , Taxane Trastuzumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Aged ≥18 ≤70 year . ECOG performance status 0 1 . Life expectancy 12 week . At least one measurable lesion exists . ( RECIST 1.1 ) . Histologically cytologic confirm HER2 positive advance breast cancer fail prior therapy . Required laboratory value include follow parameter : ANC : ≥ 1.5 x 10^9/L ; Platelet count : ≥ 100 x 10^9/L ; Hemoglobin : ≥ 9.0 g/dL ; Total bilirubin : ≤ 1.5 x upper limit normal ( ULN ) ; ALT AST : ≤ 1.5 x ULN ; BUN creatine clearance rate : ≥ 50 mL/min ; LVEF : ≥ 50 % ; QTcF : &lt; 470 m female &lt; 450 m male . Signed informed consent Received previous therapy lapatinib , neratinib , pyrotinib HER2 directe tyrosine kinase inhibitor . Received previous therapy capecitabine within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>